Adaptimmune Therapeutics plc (ADAP)
NASDAQ: ADAP · IEX Real-Time Price · USD
1.580
+0.060 (3.95%)
Mar 27, 2024, 4:00 PM EDT - Market closed

Adaptimmune Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 2023202220212020201920182017201620152014
Revenue
60.2827.156.153.961.1259.5137.8314.29.870.83
Revenue Growth (YoY)
122.05%341.50%55.36%252.76%-98.11%57.28%166.47%43.84%1096.48%-
Gross Profit
60.2827.156.153.961.1259.5137.8314.29.870.83
Selling, General & Admin
73.5163.3957.3145.843.3943.631.1123.2110.382.77
Research & Development
126.51127.73111.0991.5797.598.2787.3963.7924.149.58
Operating Expenses
200.02191.11168.4137.36140.89141.87118.498734.5112.35
Operating Income
-139.74-163.97-162.25-133.41-139.77-82.37-80.66-72.8-24.64-11.52
Other Expense / Income
-27.21-1.01-4.95-3.48-2.8512.65-10.97-2.11-2.830.01
Pretax Income
-112.54-162.96-157.3-129.93-136.92-95.02-69.69-70.69-21.81-11.53
Income Tax
1.342.50.790.160.240.50.450.890.240.08
Net Income
-113.87-165.46-158.09-130.09-137.17-95.51-70.14-71.58-22.06-11.6
Preferred Dividends
0000000014.740
Net Income Common
-113.87-165.46-158.09-130.09-137.17-95.51-70.14-71.58-36.79-11.6
Shares Outstanding (Basic)
1,206967935855630584528425215148
Shares Outstanding (Diluted)
1,206967935855630584528425215148
Shares Change
24.73%3.47%9.36%35.72%7.78%10.75%24.23%97.81%44.74%-
EPS (Basic)
-0.54-1.02-1.02-0.90-1.32-0.96-0.78-1.02-1.02-0.48
EPS (Diluted)
-0.54-1.02-1.02-0.90-1.32-0.96-0.78-1.02-1.02-0.48
Free Cash Flow
-145.56-171.272.16-55.93-114.1-108.3-78.41-59.67-34.6235.47
Free Cash Flow Per Share
-0.72-1.060.01-0.39-1.09-1.11-0.89-0.84-0.971.43
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-231.82%-603.97%-2638.58%-3370.52%-12457.22%-138.42%-213.20%-512.74%-249.63%-1396.48%
Profit Margin
-188.90%-609.46%-2570.99%-3286.81%-12225.04%-160.51%-185.39%-504.15%-372.74%-1406.18%
Free Cash Flow Margin
-241.47%-630.86%35.05%-1413.14%-10169.25%-182.00%-207.25%-420.30%-350.76%4299.27%
EBITDA
-102.7-156.88-150.73-122.34-128.91-87.21-64.26-67.4-21.08-11.29
EBITDA Margin
-170.36%-577.88%-2451.33%-3090.85%-11489.57%-146.55%-169.86%-474.72%-213.54%-1368.00%
Depreciation & Amortization
9.846.086.577.598.017.815.423.290.740.24
EBIT
-112.54-162.96-157.3-129.93-136.92-95.02-69.69-70.69-21.81-11.53
EBIT Margin
-186.68%-600.26%-2558.12%-3282.72%-12203.48%-159.68%-184.20%-497.87%-220.99%-1397.09%
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).